Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524858 · ClinicalTrials.gov registry record · Phase 2
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04524858 is a Phase 2 study that was terminated before completion, run by Aclaris Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT04524858, a Phase 2 study, was terminated before completion, sponsored by Aclaris Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.
Interventions
- DRUG ATI-450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2021-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524858
The ClinicalTrials.gov registry entry for NCT04524858 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATI-450 is the first listed.
NCT04524858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04524858 about?
NCT04524858 is a clinical study titled "Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)". This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.
What is the current status of trial NCT04524858?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-10-23. Estimated completion is 2021-02-25.
What interventions are being tested in trial NCT04524858?
The interventions under investigation include: ATI-450 (DRUG).
Who is sponsoring clinical trial NCT04524858?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.